Keyword Analysis & Research: exelixis

Keyword Analysis


Keyword CPC PCC Volume Score Length of keyword
exelixis0.770.96367508

Keyword Research: People who searched exelixis also searched

Keyword CPC PCC Volume Score
exelixis0.180.6697760
exelixis stock0.041740644
exelixis careers0.281153911
exelixis inc stock price0.930.8132791
exelixis pharmaceuticals1.160.2466823
exelixis news0.810.8604514
exelixis pipeline0.640.588154
exelixis sasmos0.170.1801165
exelixis glassdoor0.630.5823066
exelixis logo0.90.3200447
exelixis yahoo finance0.40.2979437
exelixis address1.640.4316780
exelixis cabozantinib0.040.3420012
exelixis software0.060.2948046
exelixis bioiatriki1.440.3876689
exelixis investor relations0.510.822954
exelixis alameda ca0.980.7456688
exelixis press release0.770.1115438
exelixis yahoo message board1.10.214778

Search Results related to exelixis on Search Engine

  • Shaping the Future of Oncology for Patients l Exelixis

    exelixis.com

    https://www.exelixis.com/

    WEBExelixis is an oncology-focused biotech company innovating cancer treatments for life. Find out how we're dedicated to giving more patients hope for the future.

    DA: 74 PA: 37 MOZ Rank: 60

  • Exelixis, Inc. (EXEL) Stock Price, News, Quote & History - Yahoo Finance

    yahoo.com

    https://finance.yahoo.com/quote/EXEL

    WEBFind the latest Exelixis, Inc. (EXEL) stock quote, history, news and other vital information to help you with your stock trading and investing.

    DA: 95 PA: 91 MOZ Rank: 42

  • Exelixis - Wikipedia

    wikipedia.org

    https://en.wikipedia.org/wiki/Exelixis

    WEBExelixis, Inc. is a genomics-based drug discovery company located in Alameda, California, and the producer of Cometriq, a treatment approved by the U.S. Food and Drug Administration (FDA) for medullary thyroid cancer with clinical activity in several other types of metastatic cancer.

    DA: 24 PA: 6 MOZ Rank: 26

  • Advancing Science for Cancer Treatments l Exelixis

    exelixis.com

    https://www.exelixis.com/inside-exelixis/

    WEBAt Exelixis, the ultimate definition of success is our ability to help more patients living with cancer. Michael M. Morrissey, Ph.D. President and Chief Executive Officer. Discover how we're expanding our product portfolio and West and East coast footprints to propel oncology innovation forward.

    DA: 26 PA: 5 MOZ Rank: 39

  • Exelixis Announces Detailed Results of Phase 3 CONTACT-02 …

    exelixis.com

    https://ir.exelixis.com/news-releases/news-release-details/exelixis-announces-detailed-results-phase-3-contact-02-pivotal

    WEBJan 25, 2024 · Exelixis Announces Detailed Results of Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer Presented at ASCO GU 2024 | Exelixis, Inc.

    DA: 23 PA: 36 MOZ Rank: 79

  • Building a Legacy of Oncology Excellence l Exelixis

    exelixis.com

    https://www.exelixis.com/our-story/

    WEBThroughout nearly three decades, we’ve evolved into a multi-platform cancer company. Today, we are innovating with both small molecules and biotherapeutics to build a diversified portfolio of cancer treatments that give patients hope for the future.

    DA: 48 PA: 71 MOZ Rank: 49

  • Exelixis Announces Initiation of the STELLAR-305 Phase 2/3 …

    exelixis.com

    https://ir.exelixis.com/news-releases/news-release-details/exelixis-announces-initiation-stellar-305-phase-23-pivotal-trial

    WEBDec 4, 2023 · Exelixis Announces Initiation of the STELLAR-305 Phase 2/3 Pivotal Trial Evaluating Zanzalintinib in Combination with Pembrolizumab in Patients with Previously Untreated Recurrent or Metastatic Head and Neck …

    DA: 78 PA: 42 MOZ Rank: 89

  • Accelerating New Medicines for Cancer l Exelixis

    exelixis.com

    https://www.exelixis.com/development/

    WEBDevelopment. We are committed to accelerating the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Developing new medicines is an iterative process. After testing potential compounds in labs and selecting drug candidates to study further, Exelixis conducts research and clinical trials to compile data ...

    DA: 27 PA: 56 MOZ Rank: 24

  • Developing a Novel Pipeline of Cancer Therapies l Exelixis

    exelixis.com

    https://www.exelixis.com/discovery-engine/

    WEBData-driven and science-first. As we seek to improve the treatment of patients with cancer, Exelixis is addressing a broad array of targets selected based on rigorous scientific and clinical evidence with the goal of developing a diverse …

    DA: 33 PA: 50 MOZ Rank: 76

  • Exelixis Announces Initiation of the STELLAR-303 Phase 3 …

    exelixis.com

    https://ir.exelixis.com/news-releases/news-release-details/exelixis-announces-initiation-stellar-303-phase-3-pivotal-trial

    WEBJun 21, 2022 · ALAMEDA, Calif. -- (BUSINESS WIRE)--Jun. 21, 2022-- Exelixis, Inc. (Nasdaq: EXEL) today announced the initiation of STELLAR-303, a phase 3 pivotal trial evaluating XL092 in combination with atezolizumab versus regorafenib in patients with metastatic colorectal cancer (CRC) that is not microsatellite instability-high or mismatch …

    DA: 88 PA: 85 MOZ Rank: 89